JACCKaulOriginal Research

Sanjay Kaul works in General / Preventive / Lipids affiliated with Cedars-Sinai Medical Center.
Sanjay Kaul, MD, is a cardiologist and professor of medicine at Cedars-Sinai Medical Center in Los Angeles. He has served on national committees of the American College of Cardiology, American Heart Association, and American Diabetes Association, as well as FDA advisory committees. His research focuses on clinical trials, antithrombotic therapies, and cardiovascular outcomes.
308 pubs · 31,897 cites · h-index 73
MBBS
University of Kashmir (Government Medical College)
1984
Attending Cardiologist and Professor of Medicine
Cedars-Sinai Medical Center
Fellow, Cardiovascular Disease
University of Iowa Hospitals and Clinics · 1990 - 1993
JACCKaulOriginal Research
General / Preventive / Lipids · Cedars-Sinai Medical Center
reinforce previous reports indicating that the advantage of TAVR over SAVR is not constant over time and might disappear or be reversed with longer follow-up.
Journal of the American College of CardiologyKaul
The Annals of Thoracic SurgerySousa‐Uva et al.review
Urges caution expanding TAVI in low-risk patients; leaves long-term durability open for prospective randomized trials.
JACCPeng et al.Original Research
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)Lee et al.Meta-Analysis
JACCTajrishi et al.Human Clinical Trial
JACCHolmes et al.Guideline
JACCDiamond et al.review
Adopting Bayesian statistical methods in cardiovascular megatrials could provide more clinically relevant interpretations of therapeutic benefit than conventional p-values.
JACCSpertus et al.Original Research
JACCHalperin et al.Guideline
Provides the 2015 ACC Core Cardiovascular Training Statement (COCATS 4) for cardiology fellowship training.
JACCHolmes et al.Original Research
EHJHead et al.review
This methodological review highlights the complexities, pitfalls, and proper interpretation of non-inferiority trial designs in cardiovascular research.
European Journal of Cardio-Thoracic SurgeryMilojevic et al.review
Methodological flaws in START YOUNG warrant caution interpreting its results; leaves TAVI-SAVR non-inferiority open in patients aged 65-75.
International Journal of CardiologyBarili et al.meta-analysis
While TAVI shows an early benefit over SAVR, there are no significant differences in the composite of death or stroke at 5 years follow-up regardless of baseline surgical risk.

Canadian Journal of CardiologyHeuts et al.review
Equips clinicians to apply Bayesian methods to trial data; extends reanalysis options for cardiovascular RCTs.

European Journal of Cardio-Thoracic SurgeryMilojevic et al.Original Research
The aim of this study was to identify methodological variations leading to varied recommendations between the American College of Cardiology (ACC)/American Heart Association (AHA) and the European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) valvular heart disease guidelines and to suggest foundational steps towards standardizing guideline development.